3DR is the standard of care in HIV

Discussion in 'GlaxoSmithKline' started by anonymous, May 17, 2019 at 2:01 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I sell Dovato and Juluca. I take Triumeq and am compliant. If I were to switch, I would go to Biktarvy or Tivicay+Descovy.

    My customers respect my honesty.
     

  2. anonymous

    anonymous Guest

    One of the docs I visit said this:
    "You would be hard pressed to find classically trained ID physicians with actual expertise in HIV use 2DR. Most people writing prescriptions for 2DR are mid-levels or physicians who haven't trained at major fellowship programs across the country. My alma mater would've have taken physicians to task for even suggesting that patients who live in the most chaotic environments and with less than perfect adherence should be subjected to a 2DR just because it is new."
    Couldn't have said it better myself. How many big name academic professors are actually talking about the benefits of 2DR in journals. Zero. Because there is nothing new or revolutionary about removing one of your own drugs from your own 3DR and then waving frantically going "Voila! 2 is as good as 3"
    The company is in serious delusional echo chamber mode. They are convinced that Cab will revolutionize monthly Rx of HIV.
    The only space where injectables do well is where there are no oral options. In fact developing non injectable options in that space is considered "revolutionary and paradigm shifting," the exact thing that Viiv execs are telling us Cab is.
     
  3. anonymous

    anonymous Guest

    The only reason we went with a 2DR strategy is because of ABC and we knew that Biktarvy was coming. Triumeq is a damn good drug, but the ABC and CV concerns have always been an obstacle despite what corporate tells us.

    I bet if we had another NRTI similar to TAF we would have “launched” an improved Triumeq with DTG/3TC/??? and continued to grow business. Nope, we bailed on Triumeq and went all in on what will turn us into a niche player with lower shares for sure. Triumeq is more expensive than Dovato, thus we will have to sell more of it to offset losses with Triumeq.

    Not bitter, just a realist.
     
  4. anonymous

    anonymous Guest

    Real chicken little. Get out and do your job. Dovato will be fine. Cab is coming..and spare me the doom and gloom. We have a wonderful portfolio and more in the pipeline. Like I said, DO YOUR JOB!!! If you are sooooooo worried...just leave. Thank you.
     
  5. anonymous

    anonymous Guest

    Lol. Gilead here - yes keep your mindset for my sake.

    You guys suck beyond suck but thanks for the laugh
     
  6. anonymous

    anonymous Guest

    Amazing how arrogant people like you hiding in the closet are typing on a keyboard. I won’t leave for the same reason that you and most of us at ViiV wont. I like the salary, the car, and the low sales pressure. I do believe 3DR including Triumeq is a more durable choice than Dovato/Juluca. Just because I work here I don’t have to guzzle koolaid. I will just play the GSK and ViiV survivor game along with you and my pod.